Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 2
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or postmenopausal or surgically sterilized female subjects, 50 years of age or older;
- Documented diagnosis of type 2 diabetes as defined by the American Diabetes Association;
- Diagnosis of type 2 diabetes for at least 3 months before screening;
- Subjects on stable diabetes treatment regimens (receiving oral hypoglycemics with or without insulin) for at least 2 months before screening;
- Screening and pre-randomization glycosylated hemoglobin (HbA1c) <10.0%, according to central laboratory;
- Body mass index (BMI) between 25 and 38 kg/m2
- Subjects willing to perform specified home blood glucose monitoring and comply with all study protocol requirements;
- Signed informed consent.
Exclusion Criteria:
- Serum creatinine >2 mg/dL;
- Fasting triglycerides >1000 mg/dL;
- Albuminuria >200 mg/24 hours;
- Positive mammography (if female) or prostate-specific antigen (PSA) or prostate examination for cancer (if male);
- Use of oral or parenteral glucocorticoids in the 30 days before screening;
- Use of any experimental or marketed growth hormone, growth hormone secretagogues, insulin-like growth factor-1 (IGF-1), or insulin-like growth factor binding protein-3 (IGFBP-3) during the previous 6 months;
- Subjects with two or more severe hypoglycemia episodes within the past 6 months, or any hospitalization or emergency room visit due to poor glycemic control within the past 6 months. Similarly, during the lead-in period, any subject with more than one severe hypoglycemic episode or any hospitalization or emergency room visit due to poor glycemic control will be excluded from randomization;
- History of or presence of active concomitant conditions or diseases (e.g., myocardial infarction, poorly controlled hypertension, thyroid disease, rheumatoid arthritis, seizure disorder, diabetic neuropathy, diabetic retinopathy [except subjects with only microaneurysms on fundus examination]) that would interfere with the protocol conduct and endpoint measurements;
- Subjects with a major surgical operation during the 30 days before screening;
- Subjects with known hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma;
- Current cancer or history of cancer, except non-melanomatous skin cancer;
- Subjects with active infection at any body site or a history of severe infection (requiring oral or parenteral treatment) during the 30 days before screening;
- Subjects with clinically significant abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor);
- Subjects with allergy to synthetic growth hormone products or their excipients;
- Subjects who had previously received growth hormones in any clinical trial;
- Participation in a trial of an experimental drug or device within 90 days before screening.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
|---|
|
Change from baseline in relative insulin response
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
|---|---|
|
Change from baseline in glycosylated hemoglobin (HbA1c)
|
|
|
Change in mean daily serum glucose concentrations
|
Home blood glucose will be obtained four times per day (before breakfast, lunch, and dinner, and at bedtime) using a standard blood glucose meter
|
|
Changes in the number of dose adjustments per week for insulin and/or oral hypoglycemic agents
|
|
|
Number of subjects with a change in the control of diabetes
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- TH9507/II/Diabetes/006
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .